Evidence map›Paper›PMID 39749707›Full record

ReviewMolecular medicine reports2025

Annexin A1: The dawn of ischemic stroke (Review).

Chen Tang, Rui Lan, Dong-Rui Ma, Min Zhao, Yong Zhang, Hong-Yu Li, Shuang Liu, Bo-Yang Li, Jie-Li Yang, Hui-Jie Yang and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chen Tang *Department of Encephalopathy, The First Affiliated Hospital of Henan University of Chinese Medicine, The First Clinical Medical College of the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan 450000, P.R. China.
Rui Lan *Department of Encephalopathy, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan 450000, P.R. China.
Dong-Rui MaAcademy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, Henan 450000, P.R. China.
Min ZhaoDepartment of Encephalopathy, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan 450000, P.R. China.
Yong ZhangDepartment of Traditional Chinese Medicine, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China.
Hong-Yu LiDepartment of Encephalopathy, The First Affiliated Hospital of Henan University of Chinese Medicine, The First Clinical Medical College of the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan 450000, P.R. China.
Shuang LiuDepartment of Encephalopathy, The First Affiliated Hospital of Henan University of Chinese Medicine, The First Clinical Medical College of the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan 450000, P.R. China.
Bo-Yang LiDepartment of Encephalopathy, The First Affiliated Hospital of Henan University of Chinese Medicine, The First Clinical Medical College of the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan 450000, P.R. China.
Jie-Li YangDepartment of Encephalopathy, The First Affiliated Hospital of Henan University of Chinese Medicine, The First Clinical Medical College of the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan 450000, P.R. China.
Hui-Jie YangDepartment of Encephalopathy, The First Affiliated Hospital of Henan University of Chinese Medicine, The First Clinical Medical College of the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan 450000, P.R. China.
Zhen-Qiang ZhangAcademy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, Henan 450000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ischemic stroke is a prevalent clinical condition that poses a significant global challenge. Developing innovative strategies to address this issue is crucial. Annexin A1 (ANXA1), a key member of the annexin superfamily, performs various functions, such as inhibiting inflammatory factor release, promoting phagocytosis, and blocking leukocyte migration. Evidence indicates that ANXA1 plays a pivotal role in the pathogenesis of ischemic stroke. The present article reviews involvement of ANXA1 in anti‑atherosclerosis, inflammatory processes, blood‑brain barrier protection, platelet aggregation and anti‑apoptotic mechanisms. The potential applications of ANXA1 in treating ischemic stroke are also explored.

Indexed as

Annexin A1Ischemic StrokeAnimalsApoptosisBlood-Brain BarrierHumansInflammationPlatelet AggregationAnnexin A1ANXA1 protein, humanannexin‑A1arteriosclerosisblood‑brain barrierinflammationischemic stroke

Identifiers

PMID39749707
PMCPMC11726294

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.